RESUMO
Acute bacterial skin and skin structure infections (ABSSSI), also referred to as skin and soft tissue infections, or skin and skin structure infections, with or without osteomyelitis (OM) in diabetic foot are complications of diabetes. Quinolones are a widely used class of antibiotics in ABSSSI and OM, and photosensitivity is among their adverse reactions. Its appearance may falsely indicate treatment failure. We describe 2 such cases. The first patient is a 49-year-old male with type 2 diabetes mellitus (DM), who presented with left lower limb ulcer with fever (39 °C) over a week. He began treatment with ciprofloxacin, clindamycin, and linezolid. Although his clinical condition and laboratory tests improved, the redness of the left lower limb increased. Clinical examination revealed redness on the face and the parts of the body that had been exposed to sunlight. The patient continued the same antimicrobial therapy and was given instructions to avoid exposure to sunlight. Redness and infection improved, and the patient was discharged. The second case is a 72-year-old male with a history of type 2 DM, admitted to hospital because of an infected ulcer of the first toe of the right limb. The patient received intravenous treatment with levofloxacin and clindamycin. On the fourth hospital day, the patient presented redness (with eczematous plaques) on his left lower limb. Clinical examination revealed that the patient's bed was placed near a window and his left limb was exposed to direct sunlight. Patient's bed was changed to avoid sun exposure. Symptoms began to improve over the next few days.
Assuntos
Diabetes Mellitus Tipo 2 , Pé Diabético , Osteomielite , Quinolonas , Masculino , Humanos , Pessoa de Meia-Idade , Idoso , Pé Diabético/complicações , Pé Diabético/diagnóstico , Pé Diabético/tratamento farmacológico , Clindamicina/uso terapêutico , Quinolonas/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Úlcera , Falha de TratamentoRESUMO
In August 2009, one case of autochthonous malaria due to Plasmodium vivax was diagnosed in Greece in a young woman residing in the Eastern Attica region. The source of infection could not be identified. No other autochthonous malaria cases have been described in the Attica region since 1974. This was a sporadic case with no evidence of further local transmission, and no more cases have been reported in Attica up to now, two years later.
Assuntos
Malária Vivax/diagnóstico , Plasmodium vivax/isolamento & purificação , Adolescente , Feminino , Grécia , Humanos , Malária Vivax/patologia , Microscopia , Parasitemia/diagnóstico , Parasitemia/parasitologia , Parasitemia/patologiaRESUMO
BACKGROUND Emphysematous pyelonephritis (EPN) is a life-threatening infection of the renal parenchyma. The purpose of this report is to present a case of EPN with distinctive imaging. CASE REPORT An 87-year-old man with a history of type 2 diabetes mellitus presented to the ER with fever and shivering, hypotension, and anuria, which is a clinical presentation of septic shock. He had recently been hospitalized at another hospital due to myocardial infarction and ischemic stroke, where a temporary urinary catheter was placed. Upon physical examination, he had right lateral abdominal pain with extension to the right renal region. Laboratory studies showed leucocytosis (WBC: 24 320/µl with 94.4% polymorphonuclear), elevated C-reactive protein 340 mg/l (NV <3.45), and acute renal failure (urea 155mg/dl NV <50 mg/dl, creatinine 4.4 mg/dl NV <1.2 mg/dl). A plain X-ray showed air was present peripheral to the right kidney, while the abdominal CT revealed air inside the right kidney and bilateral nephrolithiasis. The patient was initially put on aggressive hydration, vasoconstrictors, and hydrocortisone to treat the septic shock, and an advanced antibiotic treatment (meropenem) was initiated immediately. Blood culture grew Escherichia coli. After 3 days of treatment, he showed significant improvement in diuresis and renal function (urea 90 mg/dl, creatinine 1.0 mg/dl), with a concomitant decrease in inflammatory markers (CRP 36.7 mg/l). The antibiotic treatment was tapered to cefuroxime and metronidazole. The patient's condition improved, and he was discharged with per os antibiotic treatment. Subsequently, surgical assessment for the nephrolithiasis was suggested. CONCLUSIONS Emphysematous pyelonephritis, although rare, should be included in the differential diagnosis of fever in a diabetic patient with renal pain.
Assuntos
Complicações do Diabetes , Diabetes Mellitus Tipo 2 , Enfisema , Pielonefrite , Idoso de 80 Anos ou mais , Diabetes Mellitus Tipo 2/complicações , Drenagem , Enfisema/complicações , Enfisema/diagnóstico por imagem , Humanos , Masculino , Pielonefrite/complicações , Pielonefrite/diagnóstico por imagemRESUMO
INTRODUCTION: Dalbavancin is a new antibiotic against multi-drug resistant Gram (+) bacteria. Dalbavancin has an extremely long half-life. Current indication is skin and soft tissue infections (ABSSSI), but researchers have successfully administered it off-label to osteomyelitis (OM) patients. AIM: We present a case of successful treatment of diabetic foot (DF) OM. CASE REPORT: A 53-year-old male presented to our DF clinic, with recently diagnosed diabetes mellitus, with very bad glycaemic control (HbA1c=12,5%). He had diabetic neuropathy, but no peripheral arteriopathy. Two months before, because of an accident with hot water, he presented left foot ulcer, followed by ABSSSI and 1st toe and 1st metatarsal OM (plain x-ray findings). A multi-drug resistant Enterococcus faecium was isolated in cultures and a targeted treatment with tigecycline and daptomycin was administered. The patient also received 1,5 gr dalbavancin upon discharge. 2 weeks later, he continued treatment at home with linezolid and tedizolid. A complete medical record with patient's history, informed consent and relative literature was sent to Greek National Health Care Organization (EOPYY), requesting administering off-label another 1,5 gr dalbavancin. In the meanwhile, he was admitted for iv tigecyclin, and continued treatment with linezolid at home. He finally received a second dose of 1,5 g dalbavancin. Patient received totally 14 weeks' targeted therapy, mostly off-hospital. When he completed treatment, foot was in excellent condition and x-ray had significantly improved. CONCLUSION: Dalbavancin, due to its extremely long half-life, could potentially be the drug of choice for OM caused by multi-drug resistant Gram (+) cocci, in order to avoid hospitalization, especially on non-complient patients. Further research is necessary.
Assuntos
Antibacterianos/uso terapêutico , Pé Diabético/complicações , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Osteomielite/tratamento farmacológico , Osteomielite/etiologia , Teicoplanina/análogos & derivados , Queimaduras/complicações , Daptomicina/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Farmacorresistência Bacteriana Múltipla , Enterococcus faecium , Infecções por Bactérias Gram-Positivas/microbiologia , Humanos , Linezolida/uso terapêutico , Masculino , Pessoa de Meia-Idade , Oxazolidinonas/uso terapêutico , Teicoplanina/uso terapêutico , Tetrazóis/uso terapêutico , Tigeciclina/uso terapêuticoRESUMO
INTRODUCTION: Foot deformities and amputations are parameters that have been studied as risk factors for diabetic foot ulceration (DFU). However, inclusion of "foot deformities" and "amputations" in a single, broad variable and with reference to the severity of these deformities, may better characterize subjects who are prone to develop DFU. METHODS: The objective of the study was the examination of amputative and non-amputative foot deformities severity as risk factor for DFU in relation with the other established risk factors. A cross-sectional and case-control study was conducted from October 2005 to November 2016. One hundred and thirty-four subjects with type 1 and 2 diabetes, with and without active foot ulcers, participated. A structured quantitative interview guide was used. Univariate logistic regression analysis for the literature's established risk factors was performed, as well as for two versions of the "amputative and non-amputative foot deformities severity" variable. Subsequently, multivariate logistic regression analysis (MLRA) for three models and receiver operating characteristic (ROC) curve analysis were carried out. RESULTS: From the MLRA, only PAD (peripheral arterial disease) was significant (OR 3.56, 95% CI 1.17-10.82, P=0.025 and OR 3.33, 95% CI 1.02-10.08, P=0.033). Concerning the ROC curve analysis of the models, the one with the three categories amputative and non-amputative foot deformities severity variable, had the greatest area under the ROC curve (0.763, P<0.001). CONCLUSION: A united variable for lower extremity amputations and other foot deformities with reference to their severity, could be more helpful to the clinicians in identifying patients with diabetes at risk for foot ulceration.
Assuntos
Amputação Cirúrgica/estatística & dados numéricos , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 2/complicações , Pé Diabético/epidemiologia , Deformidades do Pé/epidemiologia , Idoso , Estudos de Casos e Controles , Estudos Transversais , Pé Diabético/etiologia , Feminino , Humanos , Modelos Logísticos , Extremidade Inferior/cirurgia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Projetos Piloto , Curva ROC , Fatores de Risco , Índice de Gravidade de DoençaRESUMO
BACKGROUND: The correlation of Clostridium difficile infection (CDI) with in-hospital morbidity is important in hospital settings where broad-spectrum antimicrobial agents are routinely used, such as in Greece. The C. DEFINE study aimed to assess point-prevalence of CDI in Greece during two study periods in 2013. METHODS: There were two study periods consisting of a single day in March and another in October 2013. Stool samples from all patients hospitalized outside the ICU aged ≥18 years old with diarrhea on each day in 21 and 25 hospitals, respectively, were tested for CDI. Samples were tested for the presence of glutamate dehydrogenase antigen (GDH) and toxins A/B of C. difficile; samples positive for GDH and negative for toxins were further tested by culture and PCR for the presence of toxin genes. An analysis was performed to identify potential risk factors for CDI among patients with diarrhea. RESULTS: 5,536 and 6,523 patients were screened during the first and second study periods, respectively. The respective point-prevalence of CDI in all patients was 5.6 and 3.9 per 10,000 patient bed-days whereas the proportion of CDI among patients with diarrhea was 17% and 14.3%. Logistic regression analysis revealed that solid tumor malignancy [odds ratio (OR) 2.69, 95% confidence interval (CI): 1.18-6.15, p = 0.019] and antimicrobial administration (OR 3.61, 95% CI: 1.03-12.76, p = 0.045) were independent risk factors for CDI development. Charlson's Comorbidity Index (CCI) >6 was also found as a risk factor of marginal statistical significance (OR 2.24, 95% CI: 0.98-5.10). Median time to CDI from hospital admission was shorter with the presence of solid tumor malignancy (3 vs 5 days; p = 0.002) and of CCI >6 (4 vs 6 days, p = 0.009). CONCLUSIONS: The point-prevalence of CDI in Greek hospitals was consistent among cases of diarrhea over a 6-month period. Major risk factors were antimicrobial use, solid tumor malignancy and a CCI score >6.
Assuntos
Clostridioides difficile , Infecções por Clostridium/epidemiologia , Infecções por Clostridium/microbiologia , Infecção Hospitalar , Hospitais , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Biomarcadores , Infecções por Clostridium/diagnóstico , Infecções por Clostridium/tratamento farmacológico , Comorbidade , Diarreia/epidemiologia , Diarreia/microbiologia , Feminino , Grécia/epidemiologia , Instalações de Saúde , Hospitalização , Humanos , Masculino , Pessoa de Meia-Idade , Razão de Chances , Vigilância da População , Prevalência , Modelos de Riscos Proporcionais , Fatores de Risco , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: Treatment has improved HIV infection prognosis, but whether risk and health care seeking behavior have improved is unclear. METHODS: New entrants to HIV care at University Hospitals of Cleveland, Ohio, between 1995 and 2002, with no history of AIDS-defining illnesses or antiretroviral exposure were included. RESULTS: Of new patients, 806 (80%) met the inclusion criteria. Median age increased during the study period(35.2 to 38.6 years; P < .001); proportions of females and non-whites increased nonsignificantly. Prevalence of AIDS-defining illnesses decreased from 1995 to 1996 (25.0% to 14.2%; P <.001) but remained stable thereafter. Category B conditions and sexually transmitted diseases decreased significantly(31.7% to 9.1%; P = .039 and 22.5% to 8.0%; P = .003), as did hepatitis B and C seroprevalence (8.3% to 3.6%; P = .05 and 26.2% to 14.3%; P = .003). Median CD4 counts and HIV RNA did not change significantly. CONCLUSIONS: Prevalence of Category B conditions, sexually transmitted diseases, and hepatitis B and C declined significantly in this study. Prevalence of AIDS-defining illnesses decreased early in the highly active antiretroviral therapy era only, whereas markers of HIV disease stage remained stable, suggesting a need for earlier recognition of infection. Decreasing sexually transmitted diseases and hepatitis coinfections suggest that HIV infection is increasingly seen in populations previously perceived at lower risk.
Assuntos
Terapia Antirretroviral de Alta Atividade , Infecções por HIV/epidemiologia , Infecções por HIV/psicologia , Aceitação pelo Paciente de Cuidados de Saúde , Adulto , Fatores Etários , Feminino , Infecções por HIV/complicações , Pesquisas sobre Atenção à Saúde , Hepatite B/complicações , Hepatite C/complicações , Humanos , Incidência , Masculino , Ohio , Medição de Risco , Infecções Sexualmente Transmissíveis/complicaçõesRESUMO
BACKGROUND: Statins are increasingly used in HIV-infected patients, but the effect of their immunomodulatory properties on antiretroviral-induced immune reconstitution is unknown. METHODS: The authors compared 6-month and 1-year changes in CD4 T-cell count, plasma HIV ribonucleic acid (RNA), and serum lipids in 69 HIV-infected patients receiving statins and 127 controls matched by age, nadir CD4 T-cell count, and hepatitis C serostatus. All patients were receiving highly active antiretroviral therapy (HAART). The authors used standard statistical tests for univariate comparisons and estimated average change in outcome measurements through repeated measures general linear models. RESULTS: Patients receiving statins had significantly higher median CD4 T-cell counts (430 vs 225 cells/microL, P < .001) and lower HIV RNA levels (2.3 vs 2.9 log10 copies/mL, P < .001) than controls. Statin-treated patients had diminished CD4 T-cell gain at 6 months, but this difference was not statistically significant at 12 months, despite similar 12-month virologic success rates. Patients receiving statins gained, on average, an estimated 60 fewer CD4 T-cells in the first 6 months than controls. CONCLUSIONS: Exposure to statins was associated with decreased CD4 T-cell gains during HAART in a cohort of HIV-infected patients, despite adequate virologic response. Studies with longer follow-up and detailed metabolic and immunologic monitoring are needed to confirm these findings and assess their significance and mechanisms.